Changes of Serum Cytokines in Hyperthyroid Graves’ Disease Patients at Diagnosis and during Methimazole Treatment

Objective: Cytokines are involved in the pathogenesis of Graves’ disease (GD), but ambiguous serum cytokine results have been described. Methods: We studied the changes in serum interleukin (IL)-1β, soluble IL-2 receptor (sIL-2R), IL-5, IL-6 and tumor necrosis factor (TNF)-α concentrations in 29 untreated GD patients before and after restoration of euthyroidism with methimazole (MMI) treatment compared to 25 control subjects. Eleven out of 29 GD patients had active Graves’ ophthalmopathy (GO). Results: Compared to controls, untreated GD patients had significantly higher median levels of serum IL-1β (18.7 vs. 34.0 pg/ml), sIL-2R (292.5 vs. 1,585.0 pg/ml), IL-5 (1.0 vs. 9.0 pg/ml), IL-6 (3.0 vs. 5.0 pg/ml) and TNF-α (8.1 vs. 16.0 pg/ml). In euthyroidism following MMI treatment, concentrations of IL-1β (25.0 pg/ml), sIL-2R (362.0 pg/ml), IL-5 (3.0 pg/ml), IL-6 (3.0 pg/ml) and TNF-α (5.0 pg/ml) declined significantly and were similar to controls. The greatest reductions were noted in sIL-2R (76.9%), TNF-α (68.8%) and IL-5 (66.6%) levels. Serum sIL-2R, IL-5 and TNF-α levels in active GO patients were significantly elevated, but no significant differences were observed in GD patients without GO. Using a multiple linear regression analysis, serum IL-1β was significantly associated with free thyroxine, sIL-2R with triiodothyronine and serum thyrotropin receptor antibody (TRAb) and TNF-α with TRAb. Conclusion: These results support the notion that serum cytokines could be used as a marker of GD activity, and the decrease in cytokine levels might be related to the achievement of euthyroidism and the immunomodulatory effects of MMI treatment.

[1]  J. Morales-Montor,et al.  The Role of Cytokines in the Regulation of Neurotransmission , 2008, Neuroimmunomodulation.

[2]  O. Tørring,et al.  TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. , 2008, European journal of endocrinology.

[3]  G. Perigli,et al.  Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. , 2007, The Journal of endocrinology.

[4]  I. Molnár.  The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy , 2007, Autoimmunity.

[5]  T. Aizawa,et al.  Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease. , 2006, Endocrine journal.

[6]  M. Rotondi,et al.  Increase of interferon‐γ‐inducible CXC chemokine CXCL10 serum levels in patients with active Graves’ disease, and modulation by methimazole therapy , 2006, Clinical endocrinology.

[7]  H. Escobar-Morreale,et al.  The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal. , 2005, European journal of endocrinology.

[8]  A. Gritzapis,et al.  Th1 and Th2 Serum Cytokine Profiles Characterize Patients with Hashimoto’s Thyroiditis (Th1) and Graves’ Disease (Th2) , 2004, Neuroimmunomodulation.

[9]  S. Hojker,et al.  Methimazole upregulates T-cell-derived cytokines without improving the existing Th1/Th2 imbalance in Graves’ disease , 2004, Journal of endocrinological investigation.

[10]  R. Ajjan,et al.  New understanding of the role of cytokines in the pathogenesis of Graves’ ophthalmopathy , 2004, Journal of endocrinological investigation.

[11]  R. Ajjan,et al.  Cytokines in Thyroid Autoimmunity , 2003, Autoimmunity.

[12]  R. Pichler,et al.  Soluble tumour necrosis factor-alpha receptor I and interleukin-6 as markers of activity in thyrotoxic Graves' disease. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[13]  Á. Hernanz,et al.  Serum concentrations of tumour necrosis factor‐alpha (TNF‐α) and soluble TNF‐α receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function , 2002 .

[14]  V. Koppaka,et al.  anti* , 2002, Annals of Internal Medicine.

[15]  Á. Hernanz,et al.  Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. , 2002, Clinical endocrinology.

[16]  T. Kouki,et al.  Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13. , 2001, The Journal of clinical endocrinology and metabolism.

[17]  A. Bossowski,et al.  Serum Levels of Cytokines in Children and Adolescents with Graves' Disease and Non-toxic Nodular Goiter , 2001, Journal of pediatric endocrinology & metabolism : JPEM.

[18]  G. A. Pinto,et al.  Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves' disease. , 2001, Thyroid : official journal of the American Thyroid Association.

[19]  M. Prummel,et al.  Both Th1‐ and Th2‐derived cytokines in serum are elevated in Graves' ophthalmopathy , 2000, Clinical and experimental immunology.

[20]  E. Roti,et al.  Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. , 2000, European journal of endocrinology.

[21]  B. Matsuura,et al.  Increased levels of serum interleukin-12 in Graves' disease. , 1999, European journal of endocrinology.

[22]  T. Yamada,et al.  [An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.

[23]  G M Besser,et al.  Serum cytokines in thyrotoxicosis. , 1999, The Journal of clinical endocrinology and metabolism.

[24]  B. Rapoport,et al.  Balance of Th1/Th2 cytokines in thyroid autoantibody synthesis in vitro. , 1999, Autoimmunity.

[25]  N. Amino,et al.  Increased serum concentration of interleukin-5 in patients with Graves' disease and Hashimoto's thyroiditis. , 1998, Thyroid : official journal of the American Thyroid Association.

[26]  M. Passeri,et al.  Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. , 1996, The Journal of clinical endocrinology and metabolism.

[27]  N. Amino,et al.  Onset of Graves' thyrotoxicosis after an attack of allergic rhinitis. , 1996, Thyroid : official journal of the American Thyroid Association.

[28]  A. Tsatsoulis,et al.  Increased serum interleukin‐1bT during treatment of zhyperthyroidism with antithyroid drugs , 1995, European journal of clinical investigation.

[29]  T. Erbas,et al.  Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment. , 1995, European journal of endocrinology.

[30]  L. Braverman,et al.  Serum interleukin-6 in amiodarone-induced thyrotoxicosis. , 1994, The Journal of clinical endocrinology and metabolism.

[31]  G. Barbesino,et al.  Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL‐2) receptor (sIL‐2R) in thyroid diseases , 1992, Clinical endocrinology.

[32]  A. Weetman,et al.  Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells , 1992, The Lancet.

[33]  E. Koukkou,et al.  High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism. , 1991, The Journal of clinical endocrinology and metabolism.

[34]  I. Chopra,et al.  A study of the serum concentration of tumor necrosis factor-alpha in thyroidal and nonthyroidal illnesses. , 1991, The Journal of clinical endocrinology and metabolism.

[35]  K. Oberdisse.  [Treatment of hyperthyroidism with antithyroid drugs]. , 1956, Deutsche medizinische Wochenschrift.